Niagen Bioscience Inc (NASDAQ: NAGE) kicked off on Tuesday, up 3.31% from the previous trading day, before settling in for the closing price of $8.45. Over the past 52 weeks, NAGE has traded in a range of $2.31-$9.18.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 16.76%. While this was happening, its average annual earnings per share was recorded 18.18%. With a float of $49.16 million, this company’s outstanding shares have now reached $77.33 million.
Let’s determine the extent of company efficiency that accounts for 104 employees. In terms of profitability, gross margin is 61.84%, operating margin of 7.76%, and the pretax margin is 8.89%.
Niagen Bioscience Inc (NAGE) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Niagen Bioscience Inc is 36.77%, while institutional ownership is 29.37%. The most recent insider transaction that took place on Mar 07 ’25, was worth 2,146. In this transaction SVP, General Counsel of this company bought 273 shares at a rate of $7.86, taking the stock ownership to the 2,251 shares. Before that another transaction happened on Dec 13 ’24, when Company’s Director sold 37,161 for $6.19, making the entire transaction worth $229,956. This insider now owns 244,179 shares in total.
Niagen Bioscience Inc (NAGE) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.02 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 18.18% per share during the next fiscal year.
Niagen Bioscience Inc (NASDAQ: NAGE) Trading Performance Indicators
Take a look at Niagen Bioscience Inc’s (NAGE) current performance indicators. Last quarter, stock had a quick ratio of 3.06. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.81. Likewise, its price to free cash flow for the trailing twelve months is 57.09.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.11, a number that is poised to hit 0.02 in the next quarter and is forecasted to reach 0.22 in one year’s time.
Technical Analysis of Niagen Bioscience Inc (NAGE)
Looking closely at Niagen Bioscience Inc (NASDAQ: NAGE), its last 5-days average volume was 1.15 million, which is a jump from its year-to-date volume of 0.8 million. As of the previous 9 days, the stock’s Stochastic %D was 88.76%. Additionally, its Average True Range was 0.45.
During the past 100 days, Niagen Bioscience Inc’s (NAGE) raw stochastic average was set at 88.81%, which indicates a significant decrease from 93.58% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 43.18% in the past 14 days, which was lower than the 87.62% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.03, while its 200-day Moving Average is $5.33. However, in the short run, Niagen Bioscience Inc’s stock first resistance to watch stands at $8.99. Second resistance stands at $9.25. The third major resistance level sits at $9.60. If the price goes on to break the first support level at $8.38, it is likely to go to the next support level at $8.03. Now, if the price goes above the second support level, the third support stands at $7.77.
Niagen Bioscience Inc (NASDAQ: NAGE) Key Stats
The company with the Market Capitalisation of 678.76 million has total of 78,684K Shares Outstanding. Its annual sales at the moment are 99,600 K in contrast with the sum of 8,550 K annual income. Company’s last quarter sales were recorded 29,130 K and last quarter income was 7,180 K.
